JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

ACE Inhibitors: Designing a Drug from a Snake's Bite

The -pril blood-pressure drugs are one of medicinal chemistry's proudest stories: a venom peptide, a guess about a missing zinc atom, and a deliberate design that turned a snakebite into a pill. It's the cleanest example of building a drug by reasoning about an enzyme's active site.

The target: an enzyme that raises blood pressure

Angiotensin-converting enzyme (ACE) is a protease — an enzyme that cuts peptides — and the cut it makes produces angiotensin II, a hormone that tightens blood vessels and raises blood pressure. Block ACE and that pressure-raising signal never gets made. So the design brief is clear: build a molecule that sits in ACE's active site and stops it cutting, a competitive inhibitor. The hard part was that, in the early 1970s, nobody had a crystal structure of ACE to look at.

The first clue came from the venom of a Brazilian pit viper, whose bite drops blood pressure. The venom contained short peptides that inhibited ACE; one of them, teprotide, even worked in patients — but it was a peptide, destroyed by the gut and useless as a pill. The team had proof the target was right and a hint at the shape that fit, but no oral drug. They needed to read the active site without seeing it.

Reasoning to the design: the missing zinc grabber

ACE belongs to the same chemical family as a known digestive enzyme, carboxypeptidase A, whose active site uses a zinc ion to do the cutting. The chemists made a leap: assume ACE works the same way, with a zinc atom in the pocket. A drug that places a strong zinc-binding group right where the cut would happen should anchor itself fiercely. This is reasoning about an active site by analogy — early structure-based design done with chemical logic instead of a crystal.

  1. Start from a small fragment that copies ACE's substrate end, so it sits in the pocket the right way round.
  2. Add a group that reaches toward the presumed zinc — first a carboxylate, later a thiol (–SH), which grabs zinc far more strongly.
  3. Run a SAR series, tuning the spacing so the zinc-grabber and the substrate-mimic both reach their spots at once.
  4. The result was captopril — small, synthetic, and orally active, the first designed ACE inhibitor.

From captopril to the -pril family

Captopril worked, but its thiol caused rash and taste problems and was easily oxidised. So the family grew by swapping the –SH for a milder carboxylate zinc-binder, giving enalapril and the long line of -prils. Many of these are prodrugs: enalapril itself binds weakly, but the body's esterases convert it to active enalaprilat, which is too polar to absorb on its own. Designing the inactive ester for oral bioavailability and letting the patient's own chemistry switch it on is a classic class-wide trick.